Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–6 of 6 results
Advanced filters: Author: "Aaron S Kesselheim" Clear advanced filters

  • The new National Center for Advancing Translational Sciences planned for the US National Institutes of Health intends to help transform biological findings into new therapeutic products. But if taxpayer funding of risky biomedical research translates into lucrative new medicines, the public should share in the economic benefits as well.

    • Jerry Avorn
    • Aaron S Kesselheim
    Comments & Opinion
    Nature Medicine
    Volume: 17, P: 1176

  • As drug prices have increased, there is also greater pressure to find ways to ensure access to medicines. An existing provision of the Bayh-Dole Act could help to lower costs for qualifying drugs in federal programs such as Medicare and Medicaid.

    • Alfred B Engelberg
    • Aaron S Kesselheim
    Comments & Opinion
    Nature Medicine
    Volume: 22, P: 576

  • A new extra-judicial pathway for challenging pharmaceutical patents has intensified patent challenges and helped to clear the way for earlier generic entry.

    • Jonathan J Darrow
    • Reed F Beall
    • Aaron S Kesselheim
    Comments & Opinion
    Nature Biotechnology
    Volume: 35, P: 1139-1141

  • There is substantial debate over the best approach for developing transformative drugs and how this might be supported. To help inform this debate by improving the understanding of the characteristics of transformative drug innovation, the authors surveyed a US-based group of ∼180 expert physicians in 15 medical specialities, who identified the drugs that they considered to be the most transformative in their fields over the past 25 years, as well as key factors affecting their opinions.

    • Aaron S. Kesselheim
    • Jerry Avorn
    Reviews
    Nature Reviews Drug Discovery
    Volume: 12, P: 425-431